Wockhardt Research Centre, Aurangabad, India.
Central Laboratories, IASO Group Hospitals, Athens, Greece.
Diagn Microbiol Infect Dis. 2021 Jul;100(3):115327. doi: 10.1016/j.diagmicrobio.2021.115327. Epub 2021 Jan 30.
Cefepime/zidebactam is in clinical development for the treatment of carbapenem-resistant Gram-negative infections. MICs of cefepime/zidebactam (1:1) and comparators against Enterobacterales (n = 563), Pseudomonas (n = 172) and Acinetobacter baumannii (n =181) collected from 15 Greek hospitals (2014-2018) were determined by reference broth microdilution method. The isolates exhibited high carbapenem resistance rates [(Enterobacterales (75%), Pseudomonas (75%) and A. baumannii (98.3%)]. Cefepime/zidebactam showed MIC of 0.5/2 mg/L, against Enterobacterales including metallo-β-lactamases (MBL)-producers. Reduced susceptibility rates to tigecycline (16.8%), colistin (47.4%), ceftazidime/avibactam (59.8%), and imipenem/relebactam (61%) indicated high prevalence of multi-drug resistance among Greek Enterobacterales. Cefepime/zidebactam exhibited MIC of 8/16 mg/L against Pseudomonas including MBL-producers. The MIC of ceftazidime/avibactam and imipenem/relebactam were high (≥32 mg/L). Cefepime/zidebactam showed MIC of 64 mg/L against A. baumannii which is within its therapeutic scope. Other antibiotics including colistin showed limited activity against A. baumannii. The activity of cefepime/zidebactam against multi-drug-resistant isolates is attributable to zidebactam mediated novel β-lactam-enhancer mechanism.
头孢吡肟/齐他培南正在开发用于治疗碳青霉烯类耐药革兰氏阴性感染。通过参考肉汤微量稀释法测定了来自希腊 15 家医院（2014-2018 年）的 563 株肠杆菌科、172 株铜绿假单胞菌和 181 株鲍曼不动杆菌的头孢吡肟/齐他培南（1:1）和对照药物的 MIC 值。这些分离株表现出高碳青霉烯类耐药率[肠杆菌科（75%）、铜绿假单胞菌（75%）和鲍曼不动杆菌（98.3%）]。头孢吡肟/齐他培南对包括金属β-内酰胺酶（MBL）-产酶菌在内的肠杆菌科的 MIC 为 0.5/2mg/L。对替加环素（16.8%）、多粘菌素（47.4%）、头孢他啶/阿维巴坦（59.8%）和亚胺培南/雷利巴坦（61%）的敏感性降低表明希腊肠杆菌科的多药耐药率很高。头孢吡肟/齐他培南对包括 MBL 产酶菌在内的铜绿假单胞菌的 MIC 为 8/16mg/L。头孢他啶/阿维巴坦和亚胺培南/雷利巴坦的 MIC 值较高（≥32mg/L）。头孢吡肟/齐他培南对鲍曼不动杆菌的 MIC 为 64mg/L，在其治疗范围内。其他抗生素如多粘菌素对鲍曼不动杆菌的活性有限。头孢吡肟/齐他培南对多药耐药株的活性归因于齐他培南介导的新型β-内酰胺增强机制。
